Safety, Pharmacokinetics and Biodistribution Studies of a β-galactoside Prodrug of Doxorubicin for Improvement of Tumor Selective Chemotherapy

Author： Devalapally Harikrishna   Rajan Kombu Subramanian   Akkinepally RaghuRam Rao   Devarakonda Rama Krishna  

Publisher： Informa Healthcare

ISSN： 0363-9045

Source： Drug Development and Industrial Pharmacy, Vol.34, Iss.8, 2008-08, pp. : 789-795

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of the tumor targeting of a FAPαα-based doxorubicin prodrug

By Huang Sichao   Fang Rui   Xu Jun   Qiu Shenghong   Zhang Huan   Du Jun   Cai Shaohui  

Journal of Drug Targeting, Vol. 19, Iss. 7, 2011-08 ,pp. : 487-496

Informa Healthcare

Access to resources Recommend Favorite

A Novel Doxorubicin Prodrug with Controllable Photolysis Activation for Cancer Chemotherapy

By Ibsen Stuart   Zahavy Eran   Wrasdilo Wolf   Berns Michael   Chan Michael   Esener Sadik  

Pharmaceutical Research, Vol. 27, Iss. 9, 2010-09 ,pp. : 1848-1860

Springer Publishing Company

Access to resources Recommend Favorite

Promoter Structure and Transcriptional Regulation of Human &bgr;-Galactoside &agr;2, 3-Sialyltransferase Genes

By  

Current Drug Targets, Vol. 9, Iss. 4, 2008-04 ,pp. : 310-316

Bentham Science Publishers

Access to resources Recommend Favorite

Bio-distribution and anti-tumor efficacy of PEG/PLA nano particles loaded doxorubicin

By Yu J. J.   Lee H. A.   Kim J. H.   Kong W. H.   Kim Y.   Cui Z. Y.   Park K. G.   Kim W. S.   Lee H. G.   Seo S. W.  

Journal of Drug Targeting, Vol. 15, Iss. 4, 2007-05 ,pp. : 279-284

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies

By Gabizon A.   Shmeeda H.  

Clinical Pharmacokinetics, Vol. 42, Iss. 5, 2003-01 ,pp. : 419-436

Adis International

Access to resources Recommend Favorite